← Edwards Lifesciences overview

Edwards Lifesciences vs Guangzhou Wondfo Biotech: why the prices moved differently

Weekly · monthly · quarterly news summaries, side by side in time

Edwards Lifesciences Corp (EW)

Q3 2026
▲3▼1

Edwards Lifesciences: Strong TAVR Growth, CMS Coverage Expansion, and TMTT Ambitions

  • Q2 2026 Sales Growth and Raised Guidance Edwards reported Q2 2026 sales of $1.74 billion, up 12.5% year-over-year, with TAVR sales up 10.5% and TMTT up 44.8%. Management raised full-year 2026 sales growth guidance for TAVR, TMTT, and total company, signaling confidence in continued momentum. This strong performance and upbeat outlook push EW's price up as investors see accelerating growth.

    This is a key new event that directly shows the company's financial health and future prospects, driving positive sentiment.

  • Updated CMS Coverage Decision for TAVR CMS updated its national coverage determination to ease patient access to TAVR, removing the coverage with evidence development requirement for symptomatic severe aortic stenosis and expanding coverage to asymptomatic severe cases. This regulatory change could enable 100-200 additional U.S. centers to perform TAVR, boosting demand for Edwards' core product and lifting EW's price.

    This is a new regulatory catalyst that expands the addressable market for Edwards' main product, directly impacting future revenue.

  • TMTT Growth Plan Targeting $2 Billion by 2030 Edwards outlined a plan to exceed $2 billion in transcatheter mitral and tricuspid revenue by 2030, anchored by PASCAL, EVOQUE, and Sapien M3. This long-term growth initiative, combined with the CMS coverage expansion, reinforces the company's transcatheter ecosystem and supports a higher valuation, pushing EW's price up.

    This new strategic target provides a clear long-term growth driver, enhancing investor confidence in future earnings.

  • $10 Million Penalty for Antitrust Violations Edwards must pay a $10 million penalty for antitrust violations related to its JC Medical acquisition, structuring payments to avoid mandatory antitrust review. The company must also establish a compliance program. This regulatory penalty creates a financial and reputational hit, weighing on EW's price.

    This is a new negative event that introduces legal and financial risks, potentially dampening investor enthusiasm.

August 2026
▲3▼1

Edwards Lifesciences: Strong TAVR Growth, CMS Coverage Expansion, and TMTT Ambitions

  • Q2 2026 Sales Growth and Raised Guidance Edwards reported Q2 2026 sales of $1.74 billion, up 12.5% year-over-year, with TAVR sales up 10.5% and TMTT up 44.8%. Management raised full-year 2026 sales growth guidance for TAVR, TMTT, and total company, signaling confidence in continued momentum. This strong performance and upbeat outlook push EW's price up as investors see accelerating growth.

    This is a key new event that directly shows the company's financial health and future prospects, driving positive sentiment.

  • Updated CMS Coverage Decision for TAVR CMS updated its national coverage determination to ease patient access to TAVR, removing the coverage with evidence development requirement for symptomatic severe aortic stenosis and expanding coverage to asymptomatic severe cases. This regulatory change could enable 100-200 additional U.S. centers to perform TAVR, boosting demand for Edwards' core product and lifting EW's price.

    This is a new regulatory catalyst that expands the addressable market for Edwards' main product, directly impacting future revenue.

  • TMTT Growth Plan Targeting $2 Billion by 2030 Edwards outlined a plan to exceed $2 billion in transcatheter mitral and tricuspid revenue by 2030, anchored by PASCAL, EVOQUE, and Sapien M3. This long-term growth initiative, combined with the CMS coverage expansion, reinforces the company's transcatheter ecosystem and supports a higher valuation, pushing EW's price up.

    This new strategic target provides a clear long-term growth driver, enhancing investor confidence in future earnings.

  • $10 Million Penalty for Antitrust Violations Edwards must pay a $10 million penalty for antitrust violations related to its JC Medical acquisition, structuring payments to avoid mandatory antitrust review. The company must also establish a compliance program. This regulatory penalty creates a financial and reputational hit, weighing on EW's price.

    This is a new negative event that introduces legal and financial risks, potentially dampening investor enthusiasm.

Latest
▲3▼1

Edwards Lifesciences: Strong TAVR Growth, CMS Coverage Expansion, and TMTT Ambitions

  • Q2 2026 Sales Growth and Raised Guidance Edwards reported Q2 2026 sales of $1.74 billion, up 12.5% year-over-year, with TAVR sales up 10.5% and TMTT up 44.8%. Management raised full-year 2026 sales growth guidance for TAVR, TMTT, and total company, signaling confidence in continued momentum. This strong performance and upbeat outlook push EW's price up as investors see accelerating growth.

    This is a key new event that directly shows the company's financial health and future prospects, driving positive sentiment.

  • Updated CMS Coverage Decision for TAVR CMS updated its national coverage determination to ease patient access to TAVR, removing the coverage with evidence development requirement for symptomatic severe aortic stenosis and expanding coverage to asymptomatic severe cases. This regulatory change could enable 100-200 additional U.S. centers to perform TAVR, boosting demand for Edwards' core product and lifting EW's price.

    This is a new regulatory catalyst that expands the addressable market for Edwards' main product, directly impacting future revenue.

  • TMTT Growth Plan Targeting $2 Billion by 2030 Edwards outlined a plan to exceed $2 billion in transcatheter mitral and tricuspid revenue by 2030, anchored by PASCAL, EVOQUE, and Sapien M3. This long-term growth initiative, combined with the CMS coverage expansion, reinforces the company's transcatheter ecosystem and supports a higher valuation, pushing EW's price up.

    This new strategic target provides a clear long-term growth driver, enhancing investor confidence in future earnings.

  • $10 Million Penalty for Antitrust Violations Edwards must pay a $10 million penalty for antitrust violations related to its JC Medical acquisition, structuring payments to avoid mandatory antitrust review. The company must also establish a compliance program. This regulatory penalty creates a financial and reputational hit, weighing on EW's price.

    This is a new negative event that introduces legal and financial risks, potentially dampening investor enthusiasm.

Guangzhou Wondfo Biotech Co Ltd (300482.CS)

Q3 2026
▲3▼1

Wondfo's first-half profit and cash recovery offset a decade-first annual loss

  • First loss in a decade as policy squeezes demand and prices Wondfo's 2025 revenue fell 31.91% and it posted its first loss since listing, hit by centralized procurement and DRG/DIP payment rules that cut test volumes and prices. The stock hit a new low, down about 72% from its peak, showing how badly policy pressure hurt the core testing business.

    Explains the main force behind the stock's slump and why investors are worried.

  • Buyback and controlling-shareholder purchases signal insider confidence The company approved a 30-60 million yuan buyback, and controlling shareholder Wang Jihua bought 1.156 million shares for about 20 million yuan, completing her 20-40 million yuan plan. Insiders putting real money in suggests they see the shares as undervalued, which can support the price.

    Shows concrete capital actions that counter the negative news and support the stock.

  • First-half profit and cash flow swing back to positive Wondfo reported first-half 2026 revenue of 1.039 billion yuan and net profit of 123 million yuan, with operating cash flow turning from a 56.31 million yuan outflow to a 423.99 million yuan inflow. Gross margin edged up, and overseas molecular diagnostics revenue jumped 228%, suggesting the worst may be passing.

    This is the key new evidence that the business is recovering, directly answering why the stock may be moving.

  • Seven new chemiluminescence registrations widen product range Wondfo received seven chemiluminescence device registration certificates covering liver, islet and heart tests. These add to its product lineup and support its push into the larger in-vitro diagnostics market, though the company says the revenue impact cannot yet be predicted.

    Shows new product momentum that could drive future growth, a fresh positive for the stock.

August 2026
▲3▼1

Wondfo's first-half profit and cash recovery offset a decade-first annual loss

  • First loss in a decade as policy squeezes demand and prices Wondfo's 2025 revenue fell 31.91% and it posted its first loss since listing, hit by centralized procurement and DRG/DIP payment rules that cut test volumes and prices. The stock hit a new low, down about 72% from its peak, showing how badly policy pressure hurt the core testing business.

    Explains the main force behind the stock's slump and why investors are worried.

  • Buyback and controlling-shareholder purchases signal insider confidence The company approved a 30-60 million yuan buyback, and controlling shareholder Wang Jihua bought 1.156 million shares for about 20 million yuan, completing her 20-40 million yuan plan. Insiders putting real money in suggests they see the shares as undervalued, which can support the price.

    Shows concrete capital actions that counter the negative news and support the stock.

  • First-half profit and cash flow swing back to positive Wondfo reported first-half 2026 revenue of 1.039 billion yuan and net profit of 123 million yuan, with operating cash flow turning from a 56.31 million yuan outflow to a 423.99 million yuan inflow. Gross margin edged up, and overseas molecular diagnostics revenue jumped 228%, suggesting the worst may be passing.

    This is the key new evidence that the business is recovering, directly answering why the stock may be moving.

  • Seven new chemiluminescence registrations widen product range Wondfo received seven chemiluminescence device registration certificates covering liver, islet and heart tests. These add to its product lineup and support its push into the larger in-vitro diagnostics market, though the company says the revenue impact cannot yet be predicted.

    Shows new product momentum that could drive future growth, a fresh positive for the stock.

Latest
▲3▼1

Wondfo's first-half profit and cash recovery offset a decade-first annual loss

  • First loss in a decade as policy squeezes demand and prices Wondfo's 2025 revenue fell 31.91% and it posted its first loss since listing, hit by centralized procurement and DRG/DIP payment rules that cut test volumes and prices. The stock hit a new low, down about 72% from its peak, showing how badly policy pressure hurt the core testing business.

    Explains the main force behind the stock's slump and why investors are worried.

  • Buyback and controlling-shareholder purchases signal insider confidence The company approved a 30-60 million yuan buyback, and controlling shareholder Wang Jihua bought 1.156 million shares for about 20 million yuan, completing her 20-40 million yuan plan. Insiders putting real money in suggests they see the shares as undervalued, which can support the price.

    Shows concrete capital actions that counter the negative news and support the stock.

  • First-half profit and cash flow swing back to positive Wondfo reported first-half 2026 revenue of 1.039 billion yuan and net profit of 123 million yuan, with operating cash flow turning from a 56.31 million yuan outflow to a 423.99 million yuan inflow. Gross margin edged up, and overseas molecular diagnostics revenue jumped 228%, suggesting the worst may be passing.

    This is the key new evidence that the business is recovering, directly answering why the stock may be moving.

  • Seven new chemiluminescence registrations widen product range Wondfo received seven chemiluminescence device registration certificates covering liver, islet and heart tests. These add to its product lineup and support its push into the larger in-vitro diagnostics market, though the company says the revenue impact cannot yet be predicted.

    Shows new product momentum that could drive future growth, a fresh positive for the stock.